epcoritamab-bysb (Epkinly)

Indications

• treatment of adults with relapsed or refractory diffuse large B-cell lymphoma

Dosage

• cycle 1
  • day 1: 0.16 mg
  • day 8: 0.8 mg
  • day 15: 48 mg (full dose) hospitalize for 24 hr after 1st full dose on day 15
  • day 22: 48 mg
• cycles 2 & 3
  • days 1, 8, 15, & 22: 48 mg
• cycles 4-9
  • days 1 & 15: 48 mg
• cycles >= 10
  • day 1: 48 mg

* cycle = 28 days

Adverse effects

• > 20%
  • cytokine release syndrome,
  • fatigue
  • musculoskeletal pain, abdominal pain
  • injection site reactions
  • pyrexia, nausea, diarrhea.
• > 10%
  • leukopenia, neutropenia, lymphopenia, anemia, thrombocytopenia

• drug adverse effects of pharmaceutical monoclonal antibodies

Mechanism of action

• bispecific CD20-directed CD3 T-cell engager

More general terms

• antineoplastic monoclonal antibody